JATT II Acquisition Corp. (JATT)
JATT II Acquisition Corp. is a blank-check company designed as a search vehicle for a business combination with a private biotechnology or life sciences company — a financial structure that buys time and capital for entrepreneurs while offering public-market investors exposure to early-stage innovation in healthcare.
The shell and its purpose
JATT II Acquisition Corp. emerged from the capital-raising machine in early 2026 as a newly organized special purpose acquisition company, or SPAC — a legal entity with no operating business of its own, designed entirely as a vehicle for finding, acquiring, and merging with a private company and taking it public. The company raised $60 million in its initial public offering on NASDAQ in April 2026, with the blessing of existing investors in JATT Ventures II L.P., the sponsorship vehicle that backed the IPO.
The SPAC structure allows founders and investors in early-stage companies to exit venture capital backing without waiting for the slow slog of traditional venture rounds. Instead of pitching endlessly to institutional investors, they pitch the SPAC’s management team directly. If the fit aligns, the SPAC merges with the private company, and the combined entity trades publicly under a new ticker — a shortcut to liquidity that has become one of the most common paths to public markets since 2020.
The search mandate
JATT II’s stated mission is to locate a business combination target in biotechnology and life sciences, sectors with persistent capital hunger and the potential for breakthrough therapies and platforms. The company gives itself 24 months from its IPO closing to announce a deal. Until it does, the $60 million raised in the offering sits in a trust account, untouchable except to return to shareholders who vote against the eventual business combination or to wind down the company if no suitable target emerges within the timeline.
The actual structure was an upsized offering: JATT II sold 6 million ordinary shares at $10 per share in the public IPO, and its sponsors and affiliates separately bought 300,000 shares in a private placement at the same price, putting $63 million into the trust and other company accounts. The 300,000 founder shares carry voting rights that influence shareholder decisions around any proposed merger.
Leadership and the bet
Dr. Someit Sidhu serves as Chief Executive Officer and Chairman, leading the search process. Nicholas Fernandez is the Chief Financial Officer. Their job is to negotiate the terms of acquisition, conduct due diligence on targets, and present the combined company’s story to shareholders for a vote. If shareholders reject the merger or simply lose patience, they can redeem their shares at the trust account value and leave, making the SPAC an exit vehicle that requires the management team to be persuasive about the target it selects.
The inherent conflict in a SPAC — its sponsors have already committed capital and bear reputational risk, while new shareholders can simply redeem — has made SPAC targets controversial. Venture-backed founders gain easy access to capital and public markets, while SPAC investors implicitly bet that the management team’s judgment about biotech and life sciences is sound and that no better opportunity will emerge within the next year and a half.
The ticking clock
Every SPAC race against time. Months spent due-diligencing targets, negotiating valuations, and preparing proxy materials eat into the 24-month window. The market price of the SPAC’s shares floats independently of the $10 redemption value, driven by sentiment about management quality and sector timing. Until a deal is announced and shareholder votes to approve it, JATT II remains a pure bet on the sponsorship team’s ability to find a life sciences company worth taking public.